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Abstract
Background: Change in high-density lipoprotein cholesterol (HDL-C) observed in large randomized controlled
trials using fibrates has varied. Inconsistent cardiovascular outcomes have also been the common theme of these
trials. Subgroup analysis of even the negative trials, however, reveals significant reduction in cardiovascular
disease in patients with low HDL-C and high triglycerides. We wished to study HDL-C change following fibrate
therapy in our lipid clinic and determine the factors associated with HDL-C change.
Methods: Data were collected from case notes of patients started on fibrates (n= 248) between 2002 and 2008 in
the lipid clinics at Heart of England NHS Foundation Trust. Regression analyses were carried out to determine
factors associated with changes in HDL-C.
Results: Linear regression analysis revealed that HDL-C change was associated with pretreatment HDL-C
(P < 0.001), diabetes (P = 0.004) and treatment duration (P = 0.036). Multiple regression analysis with all of the
factors in the model suggested that they were independent. Patients with a baseline HDL-C < 1.0mmol/L
showed a greater HDL-C increase when compared to patients with a baseline HDL-C ‡ 1.0mmol/L; HDL-C
< 1.0mmol/L (increase of 0.15mmol/L, linear regression: c = 0.14, 95% confidence interval 0.05–0.30, P < 0.001)
and HDL-C ‡ 1.0 (increase of 0.002mmol/L, linear regression: reference category). A similar relationship be-
tween change in HDL-C and baseline HDL-C was observed within groups stratified by patient characteristics
(apart from those on concurrent statin therapy and females).
Conclusions: Our results may explain the discrepancies observed in some randomized controlled trials whereby
subgroup analysis of patients with the metabolic syndrome appeared to show benefit whereas this was absent in
the total cohort. Thus, future interventional studies using fibrates should perhaps focus on patients with low
HDL-C levels.
Introduction
The association between low high-density lipoproteincholesterol (HDL-C) and cardiovascular disease was
initially observed nearly 60 years ago.1 Since then, epide-
miological evidence has accumulated confirming the link
between HDL-C and cardiovascular disease.2,3 This associa-
tion is observed to be independent of low-density lipoprotein
cholesterol (LDL-C) and exists even following reduction of
LDL-C to low levels with statin treatment.4,5 Similarly there
is evidence from epidemiology studies of a relationship
between elevated triglycerides (TG) and cardiovascular
disease.6
There are many potential mechanisms by which HDL-C
can affect progression of atherosclerosis. These include efflux
of cholesterol from arterial walls, prevention of endothelial
dysfunction, and possession of both antiinflammatory and
antioxidant properties.7–10
Fibrates bind and activate peroxisome proliferator-
activated receptor-a (PPAR-a), leading to the activation of a
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nuclear transcription factor that in turn regulates expression
of genes involved in regulating fatty acid and lipoprotein
metabolism.11–13 These include genes coding for apoli-
porpotein AI (Apo AI), Apo AII, Apo C-III, lipoprotein lipase
(LPL), adenosine triphosphate (ATP)-binding cassette trans-
porter 1 (ABCA1), chosteryl ester transfer protein (CETP),
scavenger receptor class B1(SR-B1), and ApoA5.14 The effect
on the lipid profile following fibrate therapy includes a
modest decrease in LDL-C concentrations, a variable increase
in HDL-C concentrations, and a greater reduction in TG
levels.15 Increase in HDL-C levels following fibrate treat-
ment has been reported to be maximal in patients with low
HDL-C at baseline.16 Kornitzer et al. reported a significant
15.2% mean increase in HDL-C in 1,334 patients after
6 months of treatment with 200mg of micronized fenofi-
brate.16 Patients with baseline HDL-C equal or lower than
0.91mmol/L (35mg/dL) demonstrated a larger significant
increase of 37.9%.
HDL-C increases following fibrate therapy in large inter-
vention studies have varied significantly. Baseline and per-
centage increase in HDL-C observed with fibrates are as
follows: Veterans Affairs High-Density Lipoprotein Inter-
vention Trial (VAHIT; gemfibrozil), baseline 0.8mmol/L,
increase 6.3%; Bezafibrate Infarction Prevention Study (BIPS;
bezafibrate), baseline 0.9mmol/L, increase 17.9%; Action to
Control Cardiovascular Risk in Diabetes (ACCORD),
0.98mmol/L, increase 8.4%; Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD; fenofibrate), baseline
1.1mmol/L, increase 2.6%; Helsinki Heart Study (HHS;
gemfibrozil), baseline 1.2mmol/L, increase 8.2%. In contrast
with the consistent results observed following reduction in
LDL-C in statin trials [Scandinavian Simvastatin Survival
Study (4S),17 West of Scotland Coronary Prevention Study
group (WOSCOPS),18 Heart Protection Study (HPS),4 Justi-
fication for the Use of Statins in Prevention: an Intervention
Trial Evaluating Rosuvastatin ( JUPITER19)], only VAHIT
and HHS have resulted in a significant reduction in primary
outcome. However, subgroup analysis of ACCORD,20
HHS,21 VAHIT,22 BIP,23 and FIELD24 has suggested that
cardiovascular benefits appear to be maximal in subjects
with insulin resistance and other characteristics of the met-
abolic syndrome.
The dyslipidemia clinics run at the Heart of England NHS
Foundation Trust [Good Hope Hospital (GHH) and Bir-
mingham Heartlands Hospital (BHH)] have used fibrates in
patients with severe hypertriglyceridemia and those with the
atherogenic lipoprotein phenotype. In light of the consider-
able variation in HDL-C change in the above-described fi-
brate trials, we wished to ascertain the changes in HDL-C
following fibrate treatment in our clinical setting. We also
wished to determine if the observed HDL-C change was
associated with any pretreatment baseline characteristics.
Patients and Methods
Patients started on fibrates between 2002 and 2008 in the
lipid clinics run by the Heart of England NHS Foundation
Trust were identified from the electronic patient record da-
tabases by using appropriate search keywords. Data were
collected from 248 consecutive case notes of patients: GHH,
150 patients; BHH, 98 patients. The proportion of Asian
patients varied between the two sites [GHH, 5 patients
(3.3%); BHH, 19 patients (19.4%)]. Lifestyle advice was given
to all patients at the initial appointment and this preceded
fibrate treatment. The prefibrate treatment total cholesterol
(TC), TG, HDL-C, calculated LDL-C, and creatinine concen-
trations were obtained from the pathology database just
prior to fibrate initiation. The posttreatment levels were the
most recent results available (up to March 30, 2009) or prior
to addition of further agents that could influence lipid values
(including medication used in the treatment of dyslipidemia
or diabetes).
TC, TG, and HDL-C levels were measured on the Roche
Modular P800 platform analyzer in both sites using Roche
reagents. LDL-C was calculated on the laboratory computer
system using the Friedwald equation when TG and HDL-C
values were available and when TG levels were below
4.5mmol/L. The data were entered on an Excel spreadsheet
and then transferred to the STATA (version 8.0 for Windows)
statistics program for analysis. A paired t-test was performed
to determine significant change in HDL-C following fibrate
treatment. Linear and multiple regression analyses were
carried out to study factors that were associated with change
in HDL-C. When the independent variable was not contin-
uous in these regression analyses, one characteristic of the
variable was chosen as the reference category. All of the
other characteristics of that variable were then factorized and
compared to the reference category with regard to the se-
lected outcome (dependent variable). Thus the ability to
factorize variables allowed multiple comparisons to be made
on a single model.
Results
Demographic details in patients treated with fibrates
The characteristics of the patients studied are presented in
Table 1. Males made up 73% of our patient group. Diabetes
and hypertension requiring treatment was observed in 34%
and 53.6% of patients, respectively. Amongst patients with
diabetes, the mean pre- and posttreatment glycosylated he-
moglobin (HbA1c) values were 8.1% and 7.9%, respectively
(paired t-test, p= 0.96). Fenofibrate was the most commonly
prescribed fibrate (213 patients, 85.9%) followed by bezafi-
brate (27 patients, 10.9%). Of the patients on fenofibrate,
76.5% were on 160mg daily followed by 17.1% on 267mg
daily. Statins were prescribed in 131 (52.8%) patients before
fibrates were started.
The dyslipidemia characterizing the metabolic syndrome
includes TG above 1.7mmol/L and HDL-C below 1.0mmol/
L and 1.3mmol/L in males and females, respectively.25
Among our patients, 44.6% of males and 60.3% of females
had pretreatment HDL-C in keeping with the metabolic
syndrome. The large majority of patients (96.8%) had pre-
treatment TG above 1.7mmol/L. This suggests that fibrates
in our practice were primarily prescribed in patients with
hypertriglyceridemia. Not surprisingly, baseline HDL-C was
significantly associated with TG.
Change in HDL-C following fibrate treatment
HDL-C increased significantly (paired t-test, p= 0.033)
following fibrate treatment by a mean of 0.059mmol/L in
the total patient group (median 0.02mmol/L, range:
- 1.0mmol/L to + 1.45mmol/L). We then carried out sepa-
rate linear regression analysis with HDL-C change as the
outcome (dependent variable) and patient characteristics and
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pretreatment lipid and creatinine concentrations as inde-
pendent variables. The results are presented in Table 2,
model 1. Duration of treatment, diabetes, and pretreatment
HDL-C were significantly associated with change in HDL-C.
All three of these factors were entered simultaneously into a
multiple regression model with change in HDL-C once again
the dependent variable (Table 2, model 2). It appears that all
three factors were independently associated with change in
HDL-C following fibrate treatment. Examination of the co-
efficients suggested that lower levels of pretreatment HDL-C
(coefficient = - 0.32) were associated with greater increases in
HDL-C. Patients with diabetes had a significantly different
response (coefficient - 0.16) to those without diabetes (ref-
erence group) with regard HDL-C change. Whereas HDL-C
in patients with diabetes decreased by a nonsignificant
0.06mmol/L (P = 0.19, paired t-test), patients without dia-
betes demonstrated a significant increase in HDL-C of
0.10mmol/L (P= 0.0002, paired t-test) following fibrate
treatment. No difference in TG reduction was seen in pa-
tients with diabetes (TG decrease of 4.2mmol/L) and those
without diabetes (TG decrease of 4.3mmol/L). Similarly,
there was no significant difference in TG reduction between
Table 1. Demographic Details of Patient Cohort
n % Mean/SD Median Range
Age (years) 243 52.0/11.1 51.6 19.1–81.8
Duration of fibrate treatment (years) 221 1.8/3.1 0.5 0.02–8.0
Males 181/248 73.0
Females 67/248 27.0
Myocardial infarction 30/245 12.2
Angina 44/240 18.3
Hypertension 128/239 53.6
Diabetes mellitus 84/247 34.0
Patients on statins 131/248 52.8
Nonsmokers 64/231 27.7
Ex-smokers 119/231 51.5
Current smokers 48/231 20.8
Gout 25/247 10.1
Alcohol: 0 units 58/222 26.1
Alcohol: 0–28 units/week 117/222 52.7
Alcohol: > 28 units/week 47/222 20.8
Pre-fibrate treatment values
TC (mmol/L) 247 6.8/2.5 6.2 3.4–20.2
TG (mmol/L) 246 8.1/8.0 5.9 0.7–58.1
HDL-C (mmol/L) 215 1.1/0.4 1.1 0.3–2.8
Creat (mmol/L) 229 87.0/22.8 85 33–218
Post-fibrate treatment values
TC (mmol/L) 243 5.5/1.4 5.3 2.2–11.4
TG (mmol/L) 243 3.8/4.0 2.8 0.5–34.4
HDL-C (mmol/L) 231 1.20.4 1.1 0.2–2.6
Creat (mmol/L) 235 93.8/22.4 91 52–211
SD, standard deviation; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; creat, creatinine.
Table 2. Association Between Patient Characteristics and Pretreatment Lipid Levels
and the Change in High-Density Lipoprotein Cholesterol Following Fibrate Therapy
n c 95% CI P r2
Model 1: Separate linear regression models between the change seen in HDL-C after fibrate treatment and individual patient
characteristics
Age 198 0.0015 - 0.0026/0.0056 0.48 0.0025
Male 203 - 0.03 - 0.13/0.068 0.55 0.0018
Diabetes mellitus 202 - 0.13 - 0.23/–0.042 0.004 0.0397
Pre-fibrate TC (mmol/L) 203 0.006 - 0.015/0.027 0.57 0.0016
Pre-fibrate TG (mmol/L) 203 - 0.0069 - 0.016/0.001 0.097 0.0136
Pre-fibrate HDL-C (mmol/L) 203 - 0.29 - 0.42/–0.17 < 0.001 0.0969
Pre-fibrate creatine (mmol/L) 198 0.0012 - 0.00081/0.0033 0.25 0.007
Duration of treatment 184 0.017 0.0032/0.031 0.016
Model 2: multiple regression analysis between the change seen in HDL-C after fibrate treatment and pre-treatment HDL-C,
Diabetes and duration of treatment in the same model
HDL-C 183 - 0.32 - 0.45/–0.20 < 0.001 0.2
Diabetes mellitus - 0.16 - 0.25/–0.075 < 0.001
Duration of treatment 0.014 0.00089/0.026 0.036
CI, confidence interval; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol.
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males (TG decrease 4.7mmol/L) and females (TG decrease
3.1mmol/L).
Interestingly, baseline TG was not significantly associated
with change in HDL-C (Table 2). Change in HDL-C when
patients were stratified by baseline TG was as follows:
0.095mmol/L (quartile 1, TG < 3.9), 0.060mmol/L (quartile
2, TG 3.9–5.3), 0.017mmol/L (quartile 3, TG 5.4–8.0), and
0.067mmol/L (quartile 4, TG > 8.0). The differences among
these four groups were not significant. The change in TG
[coefficient = - 0.001 (95% CI - 0.011–0.008, P = 0.75)] was
also not significantly associated with change in HDL-C.
We then studied the association between pretreatment
HDL-C and change in HDL-C in greater detail. The pre-
treatment HDL-C was categorized into four groups: HDL-C,
< 0.8mmol/L (n = 34); HDL-C, 0.8–1.00mmol/L (n= 70);
HDL-C, 1.01–1.2mmol/L (n = 38); and HDL-C, > 1.2mmol/L
(n = 73). The change in HDL-C is presented in Fig. 1. We
carried out a multiple regression analysis with change in
HDL-C as outcome, and the pretreatment HDL-C categories
as a factorized variable. This analysis was corrected for
diabetes and duration of fibrate treatment, with both en-
tered into the model as co-variables. Pretreatment HDL-C
> 1.2mmol/L was the reference category, and the other
pretreatment HDL-C categories were compared to this. It
was observed that patients in the HDL-C < 0.8mmol/L
[coefficient= 0.22 (95% CI 0.090–0.35, P= 0.001] and HDL-C
0.8–1.00mmol/L [coefficient= 0.14 (95% CI 0.032–0.24, P=
0.011] categories were significantly different to the reference
category in relation to the change in HDL-C following treat-
ment. This was not observed in the group with pretreat-
ment HDL-C of 1.01–1.20mmol/L [coefficient= 0.034 (95% CI
- 0.095–0.1, P= 0.60]. To simplify the above finding we strati-
fied the patients into those with HDL-C £ 1.00mmol/L,
and those with HDL-C > 1.00mmol/L (reference group).
Patients withHDL-C £ 1.00 had a significantly greater increase
in HDL-C following fibrate treatment when compared to
the reference group [coefficient= 0.15 (95% CI 0.066–0.24,
P= 0.001]. Similarly, we stratified the patients by pretreatment
TG levels and studied the effect on HDL-C change following
treatment. Multiple regression analysis showed no signifi-
cant differences in HDL-C change existed between the TG
categories.
Association between change in HDL-C
and pretreatment HDL-C values in patient subgroups
Our group of patients consisted of a cohort referred to
routine hospital lipid clinics with a range of patient charac-
teristics as seen in Table 1. We stratified our patient groups
by some of these characteristics and studied the relationship
between pretreatment HDL-C and change in HDL-C in each
of these groups. The association between pretreatment HDL-
C and change in HDL-C following fibrate treatment was
evident in all the subgroups apart from female patients,
those on statin treatment, and the 28 patients who were on
fibrates other than fenofibrate (Table 3). When the patients
were stratified by the specific lipid clinic they attended
(GHH, BHH), significant associations between change in
HDL-C and pretreatment HDL-C were observed with similar
coefficients (GHH, - 0.28; BHH, - 0.30). Figure 1 presents the
FIG. 1. Change in high-density lipoprotein cholesterol (HDL-C) following fibrate treatment with the patient cohort stratified
by pretreatment HDL-C concentrations.
192 RAMACHANDRAN ET AL.
change in HDL-C following fibrate treatment in relation to
categorized pretreatment HDL-C in the total cohort as pre-
viously described and in some of the above-mentioned
subgroups. We did not stratify the patients by their baseline
TG as this was significantly associated with baseline HDL-C.
Discussion
The principal aim of this study was to investigate the ef-
fect of fibrates, principally fenofibrate, on HDL-C in our
routine clinic setting. We then planned to identify factors that
may be associated with any change in HDL-C. Overall the
HDL-C increased by a mean of 0.059mmol/L following fi-
brate therapy. Change in HDL-C was significantly associated
with pretreatment HDL-C, diabetes, and duration of treat-
ment. Greater increases in HDL-C were observed in patients
with lower levels of pretreatment HDL-C, as previously
described by Kornitzer et al.16 This pattern was observed
independently in both clinics run by the trust.
In addition to confirming Kornitzer’s observation in a
routine clinic setting, we have studied this phenomenon in
greater depth. Patients with HDL-C £ 1.0mmol/L showed
significant increase in HDL-C when compared to patients
with HDL-C > 1.0mmol/L. The association between change
in HDL-C and pretreatment HDL-C was not observed in fe-
males, those on statins, and patients on fibrates other than
fenofibrate. Females are known to have higher HDL-C com-
pared to males, and this could possibly explain the lack of any
observed association. Only 3.45% (n= 2) and 24.14% (n= 14)
of females had pretreatment HDL-C concentrations below
0.8mmol/L and 1.0mmol/L, respectively; this in contrast to
10.83% (n= 17) and 44.59% (n= 70) of males. This distribution,
together with the smaller number of females in our study,
prohibited us from examining this data in further detail. Once
again the number of patients on fibrates other than fenofibrate
was too small to allow us to analyze the data further.
In our patients, we unexpectedly observed that fibrate
therapy did not increase HDL-C when they were also on
statins. In contrast, when fenofibrate was added to simvas-
tatin in the ACCORD study, HDL-C increased by a mean of
8.4%. However, the dose of simvastatin was modified in
response to changing guidelines, and similarly the dose of
fenofibrate was adjusted depending on the estimated glo-
merular filtration rate. Furthermore, it must be noted that
only 80% of the patients were on simvastatin at the end of the
study and an additional 6% of patients were taking an
alternative LDL-C–reducing agent. The effect of a statin–
fibrate combination in the FIELD study is difficult to inter-
pret due to the imbalanced statin ‘‘drop-in.’’ Statins have
also been seen to increase HDL-C. Metaanalysis of the
VOYAGER database showed that HDL-C increase following
statin treatment was greater in patients with lower pre-statin
treatment HDL-C. Although simvastatin, rosuvastatin, and
atorvastatin all increased HDL-C, the dose–response effect of
atorvastatin on HDL-C change was inverse.26 However,
none of these findings offer an explanation for our observa-
tion of insignificant HDL-C change in patients on statins.
There has been considerable speculation as to which group
of patients would benefit from fibrate treatment27 due to
mixed outcomes regarding cardiovascular events in the large
fibrate trials. However, in subgroups with low HDL-C and
raised TG, which are features of the metabolic syndrome,
there has been greater cardiovascular benefit when compared
to the complementary groups. This has generated significant
interest regarding the use of fibrates in such patients.28 Our
data showing that HDL-C increase following fibrate treatment
were observed mainly in patients with low baseline HDL-C
and may partly explain the greater cardiovascular benefits
observed in the metabolic syndrome patient subgroups.
Ours was a retrospective evaluation of the effects of fi-
brates, mainly fenofibrate, on HDL-C in a routine outpatient
setting. There are some weaknesses that are inherent to this
type of study. Unlike randomized controlled trials, there was
no inclusion or exclusion criteria. Frequency of patient follow-
up was based on clinical judgement and not trial protocol,
thus there was some missing data. Lack of accurate body mass
Table 3. Results Obtained from a Linear Regression Analysis Studying the Association Between
the Change in High-Density Lipoprotein Cholesterol (Dependent Variable) and Pretreatment
High-Density Lipoprotein Cholesterol Concentrations (Independent Variable) in Patients Stratified
by the Fibrate Used, Gender, Diabetic Status, Statin Treatment, and the Clinic Attended
Fibrate used Fenofibrate Other fibrate
n c (95% CI) n c (95% CI)
175 - 0.33 (- 0.46/- 0.20) 28 - 0.088 ( - 0.49/0.31)
Gender Male Female
n c (95% CI) n c (95% CI)
148 - 0.52 (- 0.68/- 0.36) 55 - 0.095 ( - 0.31/0.12)
Diabetes Diabetic Nondiabetic
n c (95% CI) n c (95% CI)
63 - 0.40( - 0.63/ - 0.16) 139 - 0.28 (- 0.43/- 0.14)
Statin treatment On statins Not on statins
n c (95% CI) n c (95% CI)
99 0.0032 (- 0.16/0.17) 104 - 0.53 (- 0.70/- 0.35)
Clinical setting GHH BHH
n c (95% CI) n c (95% CI)
119 - 0.28 (- 0.41/- 0.15) 84 - 0.30 ( - 0.53/ - 0.082)
A significant association between change in HDL-C and pre-treatment HDL-C was also seen in patients stratified by alcohol intake
(0 units/week, 1–28 units/week and > 28 units/week), smoking status (never smoked, ex-smoker, and current smoker) and ethnicity (Asian,
non-Asian).
CI, confidence interval; GHH, Good Hope Hospital; BHH, Birmingham Heartlands Hospital.
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index (BMI) measurements as recorded in the clinical notes
was a further limitation of our study. Despite the above
points, it is important that questions we have attempted to
address are studied in both controlled and real-world settings.
Our study has presented us with some interesting find-
ings. Whereas it is possible that the effect of baseline HDL-C
on the magnitude of HDL-C increase may reflect a regression
to the mean, it is important that this be further investigated
in appropriately designed studies that should also focus on
possible explanatory mechanisms. Furthermore, randomized
controlled trials are essential to study the effect of fibrates on
cardiovascular outcomes in patients with lower HDL-C than
investigated in fibrate trials thus far. This would negate some
of the limitations of subgroup analysis of existing studies
that we have at present.
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